A retrospective analysis of treatment switch from faricimab to aflibercept 8 mg in nAMD.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

International Ophthalmology Pub Date : 2026-10-17 DOI:10.1007/s10792-026-04237-x

Sarah Nermin Mehany, Pia Veronika Vécsei-Marlovits, Agnes Boltz

{"title":"A retrospective analysis of treatment switch from faricimab to aflibercept 8 mg in nAMD.","authors":"Sarah Nermin Mehany, Pia Veronika Vécsei-Marlovits, Agnes Boltz","doi":"10.1007/s10792-026-04237-x","DOIUrl":null,"url":null,"abstract":"Purpose: Macular neovascularization is one of the most common causes of irreversible vision loss. Intravitreal injections with anti-vascular endothelial growth factor are the treatment of choice. In recent years, new drugs such as faricimab and aflibercept 8 mg have paved the way for longer intervals between intravitreal injections. However, there are currently very few comparative studies on these longer-acting drugs.Methods: This retrospective analysis included patients with at least three consecutive intravitreal injections of faricimab due to neovascular age-related macular degeneration who were subsequently switched from faricimab to aflibercept 8 mg in 2024. The primary outcome was the change in central retinal thickness as measured by optical coherence tomography. The secondary outcome was best-corrected visual acuity.Results: 41 eyes of 38 patients were included. There were no statistically significant changes in retinal thickness. Best-corrected visual acuity showed a trend towards deterioration, however not statistically significant. One patient experienced a tear of the retinal pigment epithelium after receiving the first injection of aflibercept 8 mg.Conclusion: This retrospective analysis did not show statistically significant changes in central retinal thickness or best-corrected visual acuity after treatment switch from faricimab to aflibercept 8 mg.","PeriodicalId":14473,"journal":{"name":"International Ophthalmology","volume":"46 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Ophthalmology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10792-026-04237-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Macular neovascularization is one of the most common causes of irreversible vision loss. Intravitreal injections with anti-vascular endothelial growth factor are the treatment of choice. In recent years, new drugs such as faricimab and aflibercept 8 mg have paved the way for longer intervals between intravitreal injections. However, there are currently very few comparative studies on these longer-acting drugs.

Methods: This retrospective analysis included patients with at least three consecutive intravitreal injections of faricimab due to neovascular age-related macular degeneration who were subsequently switched from faricimab to aflibercept 8 mg in 2024. The primary outcome was the change in central retinal thickness as measured by optical coherence tomography. The secondary outcome was best-corrected visual acuity.

Results: 41 eyes of 38 patients were included. There were no statistically significant changes in retinal thickness. Best-corrected visual acuity showed a trend towards deterioration, however not statistically significant. One patient experienced a tear of the retinal pigment epithelium after receiving the first injection of aflibercept 8 mg.

Conclusion: This retrospective analysis did not show statistically significant changes in central retinal thickness or best-corrected visual acuity after treatment switch from faricimab to aflibercept 8 mg.

查看原文本刊更多论文

nAMD治疗从法利西单抗切换到阿伯西贝8mg的回顾性分析。

目的：黄斑新生血管形成是不可逆视力丧失的最常见原因之一。玻璃体内注射抗血管内皮生长因子是治疗的选择。近年来，诸如法利昔单抗和阿非利西贝8mg等新药为延长玻璃体内注射间隔铺平了道路。然而，目前对这些长效药物的比较研究很少。方法：本回顾性分析纳入了因新生血管性年龄相关性黄斑变性而至少连续三次接受法利西单抗玻璃体内注射的患者，这些患者随后在2024年从法利西单抗切换到阿非利西贝8 mg。主要结果是通过光学相干断层扫描测量视网膜中央厚度的变化。次要结果为最佳矫正视力。结果：纳入38例患者41只眼。视网膜厚度变化无统计学意义。最佳矫正视力有下降趋势，但无统计学意义。1例患者首次注射阿布西普8mg后视网膜色素上皮撕裂。结论：本回顾性分析显示，从法利西单抗切换到阿非利西贝8mg治疗后，中央视网膜厚度或最佳矫正视力没有统计学上的显著变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Ophthalmology OPHTHALMOLOGY-

CiteScore

3.20

自引率

0.00%

发文量

451

期刊介绍： International Ophthalmology provides the clinician with articles on all the relevant subspecialties of ophthalmology, with a broad international scope. The emphasis is on presentation of the latest clinical research in the field. In addition, the journal includes regular sections devoted to new developments in technologies, products, and techniques.